Clinical Trial Update: Selumetinib and Azacitidine in High Risk Chronic Blood Cancers [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of selumetinib and azacitidine in high-risk chronic myeloid leukemia and myelofibrosis is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Myelofibrosis

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Selumetinib (selumetinib)

Snippet

Sponsor: University of Chicago | Conditions: Chronic Myeloid Leukemia, Myelofibroses | Phase 1 | Status: RECRUITING